Tyler Blok wasn't awarded incentive compensation f
Post# of 148425
"In September 2024, the Compensation Committee approved the payment of non-equity incentive compensation to Tyler Blok in the amount of $100,000, representing approximately 75% of the target cash incentive he was eligible for in fiscal year 2024, based on the level of achievement of his assigned performance goals. The goals related to the lifting of the Food and Drug Administration’s clinical hold on clinical studies of leronlimab and the resolution of certain significant disputes with third parties on terms materially favorable to the Company. The Compensation Committee determined that a fourth performance goal, relating to obtaining a material strategic partnership or licensing transaction, was not met."
https://ir.stockpr.com/cytodyn/sec-filings-em...x424b3.htm